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Background/Aim: To evaluate the prevalence of pulmonary hypertension among patients
living with HIV/AIDS and to determine its contribution to cardiac dysfunction.
Method: A hospital based cross sectional study was carried out over a 6-month period at the
Jos University Teaching Hospital. The subjects were 200 confirmed HIV positive patients,
18 years of age who consented to the study. Physical examination, laboratory inves-
tigations, 2 dimensional and Doppler echocardiography were conducted on the subjects.
Results: The mean age of the patients was 38  9 years, and there were 142 females (71%).
Females were younger, mean age 36  8 years versus 41  10 years for males (p-value
<0.01). The median CD4 cell count was 312 cells/ml, there were no homosexual or intra-
venous drug user among the subjects.
Eight of the subjects had pulmonary hypertension, with a case prevalence of 4%, and this
had no relationship to CD4 cell count. Both systolic and diastolic functions were worse in
subjects with pulmonary hypertension, with a negative correlation between mean pul-
monary arterial systolic pressure (mPASP) and parameters like ejection fraction (r ¼ 0.28,
p-value 0.0003), fractional shortening (r¼ 0.21, p-value 0.003), deceleration time (r ¼ 0.13.
p-value 0.09).
Conclusion: Immune-suppression affects the cardiac function adversely and coexisting
pulmonary hypertension contributes to poor systolic and diastolic function in affected
patients. The subtle nature of presentation of pulmonary hypertension and other cardiac
dysfunctions in HIV/AIDS patients demand a high-index of suspicion and early inter-
vention if detected, to ensure better care for these emerging threats to our patients.
Copyright ª 2013, Cardiological Society of India. All rights reserved.1. Introduction
Pulmonary hypertension is one of the causes of heart disease
in HIV/AIDS and is an independent predictor of mortality in
affected patients.1e3 The first case of pulmonary hypertension
seen in HIV infected patient was described by Kim and Factor4
in 1987, subsequently the increasing report led to the inclu-
sion of HIV associated pulmonary hypertension as a distinct
entity in WHO classification at the 3rd world symposium held
in Venice in 2003.2
Majority of investigations into pathogenesis of pulmonary
arterialhypertension (PAH)havecenteredondysfunctionof the
pulmonaryvasculaturewithaprimaryfocusonendothelialand
vascular smooth muscle cells. However, the prevalence of
autoimmunity, viral infections and chronic inflammation in
association with certain form of PAH, has led some to proposethat vascular remodeling seen in PAH is secondary to immune
dysfunction, and that chronic depletion of CD4 T cells could
lead to a loss of T regulatory activity and unchecked humoral
immunity.5 This later point has been corroborated by other
workers, drawing the conclusion that conditions commonly
associated with PAH, such as systemic sclerosis and HIV, are
associated with abnormalities in CD4 T-cell function and
exhibit a similarly inflamed pulmonary vascular pathology.6,7
Pulmonary hypertension is observed in all groups of
patients with HIV irrespective of the degree of immune-defi-
ciency.8 In patients with HIV-related pulmonary hypertension
(HRPH), the median survival [300 days with conventional
therapy9] is decreased, and in most cases death is related to
pulmonary hypertension.10,11
Signs and symptoms of HIV related pulmonary hyper-
tension are nonspecific, as a result of which diagnosis is often
Table 1 e Clinical definitions used for patient
classification.
Left ventricular systolic
dysfunction
Fractional shortening <28%
Ejection fraction <50%
Without LV dilatation (LVIDD<55 mm)
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of pulmonary hypertension among HIV infected patients at
the Jos University Teaching Hospital (JUTH), North-central
Nigeria and further evaluate the contribution of pulmonary
hypertension to cardiac dysfunction.Isolated left ventricular
dilatation
LVIDD 55 mm with normal fractional
shortening (28%)
Dilated cardiomyopathy
(DCM)
Ejection fraction <50%
Fractional shortening <28%
LVIDD>55 mm, with global hypokinesia
Right ventricular
dysfunction
RVIDD30 mm or RVIDD > LVIDD
Pulmonary
hypertension
PASP 30 mmHg, and/or peak tricuspid
regurgitation (VTR) >2.5 m/s.
Mild 30e40 mmHg
Moderate 41e50 mmHg
Severe >50 mmHg
Diastolic dysfunction Grade 1 E/A <1.0
Deceleration time (DCT) > 220 ms
IVRT >92 ms (<30 years), >100 ms
(30e50 years), >105 ms (>50 years)
Grade 2 E/A 1e2
DCT 150e200 ms
Grade 3 E/A >2.0
DCT <150 ms.2. Method
2.1. Study design
This was a hospital based cross sectional study involving 200
HIV-infected cohorts, carried out betweenMay and November,
2010.Subjectswere18yearsandabove,consecutively recruited,
and gave informed consent before commencement of the
study. The following were excluded from the study; Patients
with dyspnea of respiratory origin, patients with history of
heart disease predating HIV infection, those with severe ane-
mia, and patients with Diabetes Mellitus. Also excluded were
patients with a history of significant alcohol consumption,
those with known connective tissue disease or sickle cell ane-
mia, and patients with peripartum cardiomyopathy.
2.2. Data collection
Subjects had questionnaire administered on them, based on
which those that qualified had physical examination. They
were categorized based on the NYHA questionnaire into those
with dyspnea (NYHA IeIV), classified as NYHA-positive, and
those without dyspnea as NYHA-negative. This was followed
by laboratory workup for hemoglobin concentration, CD4 cell
count, HIV viral load, serum lipid profile, Electrocardiogram,
Hepatitis B surface antigen (HBsAg) and Anti-HCV antibody.
2.3. Echocardiography
All 200 patients underwent qualitative two dimensional
transthoracic echocardiography, from which M-mode images
were derived as well as Doppler flow examination with
Aloka-SSD4000 using a 3.5 MHz transducer. Left ventricular
internal diameter (LVID) in systole and diastole, FS and EF
were determined using standard protocol.12 Using continuous
wave Doppler, sampling of peak regurgitation jet velocity
across tricuspid valve was used to estimate right ventricular
to right atrial systolic pressure gradient, according tomodified
Bernoulli equation (4  [tricuspid regurgitation jet veloc-
ity]2).13 RVSPRAP ¼ 4VTR2, PASP ¼ 4VTR2 þ RAP.
Pulmonary hypertension was defined by pulmonary arte-
rial systolic pressure (PASP) 25 mmHg at rest. Cardiac dys-
function (HRCD) was defined based on echocardiographic
findings as shown in Table 1, and subjects were either classed
as having heart disease (if they had pulmonary hypertension
or any other form of cardiac dysfunction) or without heart
disease if their echocardiography was normal.3. Statistical analysis
The data were analyzed with the Epi info version 3.5.3 (2011,
CDC Atlanta Geogia). Continuous variables were expressed asmeans  standard deviation (SD). Differences between group
means were tested by two-tailed student t-test. A Chi-square
(X2) statistics was calculated to identify associations
between categorical variables. Analysis of variance was used
to comparemean echocardiography datawhere appropriate. p
value <0.05 was considered significant.4. Results
4.1. General characteristics
The mean age of the study population was 39 years, with
majority of the study population (89%) falling within the age
range of 30e39 years and 26% being 50 years and above (Table
2). There were 142 females (71%) constituting the bulk of the
patients, majority of the subjects were married and a lot more
had at least secondary level of education, while a greater
percentage of themwere civil servants. Seventy seven percent
(77%) of our subjects were not using alcohol.
There was no significant difference in occurrence of heart
disease among the age groups, while significantly more males
had heart disease compared to females (X2 8.69, p value 0.003).
The other socio-demographic characteristic showed no sig-
nificant difference in the two groups.
4.2. HIV-related pulmonary hypertension
The case prevalence of HIV-related pulmonary hypertension
(HRPH) was 4.0%. There was no significant difference in the
case prevalence of HRPH between females (6.9%) and males
(2.8%) [X2 ¼ 1.78, p-value ¼ 0.18].
There was no significant difference in the mean age of
subjects with HRPH, 39 (9.3) years and those without HRPH, 38
(8.8) years; p ¼ 0.66. The ratio of male to female was 1:1.
Table 2 e Socio-demographic characteristics of study population.
Characteristics Frequency (n) Percentage (%) Heart disease n (%)
n ¼ 85
No heart disease n (%)
n ¼ 115
Age Groups (years)
20e29 30 1.5 14 (16.5) 16 (13.9)
30e39 89 44.5 34 (40.0) 55 (47.8)
40e49 55 27.5 22 (25.9) 33 (28.7)
50 and above 26 13 15 (17.6) 11 (9.6)
Sex
Female 142 71 34 (40) 24 (21)
Male 58 29 51 (60) 91 (79)
Marital status
Divorced 7 3.5 2 (2.4) 5 (4.3)
Married 115 57.5 49 (57.6) 67 (58.3)
Separated 6 3 3 (3.5) 4 (3.5)
Single 24 12 11 (12.9) 12 (10.4)
Widowed 48 24 20 (23.5) 27 (23.3)
Education
None 15 7.5 4 (4.7) 11 (9.6)
Informal 3 1.5 1 (1.2) 2 (1.7)
Primary 50 25 21 (24.7) 29 (25.2)
Secondary 74 37 33 (38.5) 42 (36.2)
Tertiary 58 29 26 (30.6) 31 (27)
Occupation
Civil servant 59 29.5 25 (29.4) 33 (28.7)
Craft worker 28 14 11 (12.9) 17 (14.8)
Farmers 17 8.5 9 (10.6) 8 (7.0)
Housewife 30 15 18 (21.2) 13 (15.3)
Student/Applicant 17 8.5 9 (10.6) 8 (7.0)
Traders 49 24.5 13 (15.3) 36 (42.4)
Alcohol use
Yes 46 23 20 (23.5) 26 (22.6)
No 154 77 65 (76.5) 77 (77.4)
Heart disease ¼ Presence of HIV-related cardiac dysfunction (HRCD) or HIV-related pulmonary hypertension (HRPH).
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among subjects with HRPH; the student t test shows stat-
istical significance in sex, educational status, alcohol use
and NYHA classification. But when these variables were
put in logistic regression model, only sex showed a trend
(Table 4).
Neither the duration of HIV diagnosis (p-value ¼ 0.27), nor
the duration of Highly active anti-retroviral therapy (HAART)
(p-value ¼ 0.27), had any statistically significant relationship
with the presence of HRPH.
The diagnosis of HRPH was made earlier (36 months) fol-
lowing HIV positive result than other types of HIV-related
cardiac dysfunction (HRCD) [41 months], though not sig-
nificant (p ¼ 0.27). Dyspnea as evaluated with NYHA showed
significant difference between subjects with heart disease and
thosewithout (X2¼ 5.07, p¼ 0.02), while comparingwithHRPH
subjects, it was less significant (X2 ¼ 11.5, p ¼ 0.07). Fifty per-
cent of HRPH subjects were in NYHA III and IV, compared to
30.8% of subjects with other forms of HRCD.
4.3. Pulmonary hypertension and left ventricular function
As seen in Table 5 and Fig. 1, mPASP showed negative corre-
lation to some echocardiographic parameters. It was most
evident with ejection fraction (EF) and fractional shortening
(FS), p <0.01, while deceleration time (DCT) was next withp ¼ 0.09. Another parameter noticed to have a negative cor-
relation though with non-statistically significant p-value was
left ventricular posterior wall in systole (LVPWS), p ¼ 0.27.
Subjects with pulmonary hypertension had dilated left ven-
tricle, but showed a positive correlation with coefficient of
correlation of 0.125, and p ¼ 0.08.5. Discussion
The case prevalence of HIV-related pulmonary hypertension
(HRPH) in the study was 4.0%, which is close to the prevalence
rates of 5.5% and 5% reported in the US14 and Africa.15 The
female to male ratio of HRPH in the study was 1:1, we had
more females in the study and theywere older than themales,
and older when compared with other females without HRPH.
Other works have reported female to male ratios between 1.2
and 1.6:1.16e18 Males with HRPH in our study were younger
than those without it, similar to the finding of a Swiss cohort
study.19 This is contrary to the trend in Europe where HRPH
presents at a younger age than those with other forms of
pulmonary hypertension, and unlike idiopathic PAH, which is
more common in women than inmen {ratio of men to women
1:1.7}16,17 probably owing to early presentation. Aging and
longetivity are often associated with increase in systemic
markers of inflammation, such markers include plasma
Table 3 e Comparing the socio-demographic parameters of subjects with HIV-related pulmonary hypertension and
subjects with no heart disease.
Characteristics Frequency (n) Percentage (%) No heart disease n (%)
n ¼ 115
HRPHT n (%)
n ¼ 8
X2 p-value
Age groups (years) 0.03 0.86
20e29 30 1.5 16 (13.9) 1 (12.5)
30e39 89 44.5 55 (47.8) 3 (37.5)
40e49 55 27.5 33 (28.7) 3 (37.5)
50 and above 26 13 11 (9.6) 1 (12.5)
Sex 5.75 0.02
Female 142 71 91 (79) 4 (50)
Male 58 29 24 (21) 4 (50)
Marital status 0.02 0.89
Divorced 7 3.5 5 (4.3) 0 (0)
Married 115 57.5 67 (58.3) 5 (62.5)
Separated 6 3 4 (3.5) 0 (0)
Single 24 12 12 (10.4) 1 (12.5)
Widowed 48 24 27 (23.3) 2 (25)
Education 6.87 0.01
None 15 7.5 11 (9.6) 0 (0)
Informal 3 1.5 2 (1.7) 0 (0)
Primary 50 25 29 (25.2) 2 (25)
Secondary 74 37 42 (36.2) 2 (25)
Tertiary 58 29 31 (27) 4 (50)
Occupation 0.01 0.90
Civil servant 59 29.5 33 (28.7) 2 (25)
Craft worker 28 14 17 (14.8) 0 (0)
Farmers 17 8.5 8 (7.0) 1 (12.5)
Housewife 30 15 13 (15.3) 3 (37.5)
Student/Applicant 17 8.5 8 (7.0) 1 (12.5)
Traders 49 24.5 36 (42.4) 1 (12.5)
NYHA dyspnea classification 11.5 0.07
I 30 15.2 17 (15.0) 3 (37.5)
II 16 8.1 11 (9.8) 0 (0)
III 37 18.7 16 (14.3) 3 (37.5)
IV 7 3.5 0 (0) 1 (12.5)
NYHA: New York Heart Association.
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of innate immune system later in life. Some argue that this
increase activity of innate immune system may contribute to
a long life,21 however elevatedmarkers of inflammation in the
aged are associated with disability and death.22
No risk factors were identified in subjects with HRPH. It
occurred irrespective of high CD4 cell count. This again bringsTable 4 e Logistic regression of HRPHT and other
variables.
Term Odds
ratio
95% C.I. Z-statistic p-Value
Age 1.00 0.89 1.12 0.05 0.96
BMI 1.12 0.89 1.39 0.98 0.33
CD4 cell count 0.99 0.99 1.00 0.86 0.39
Duration since
HIV diagnosis
0.78 0.52 1.17 1.19 0.24
Log_10_of_viral load 1.26 0.42 3.82 0.41 0.68
Months on HAART 1.31 0.86 2.00 1.26 0.21
Sex 7.65 0.95 61.89 1.91 0.06
CONSTANT 1.52 0.13
BMI: Body mass index.to fore the question on the role of autoimmunity; inflamma-
tory components that results from activation of innate
immune system have been linked to most chronic diseases,23
examples abounding in cardiovascular diseases involving
chronic inflammation of arterial walls mediated in part by
oxidized lipids.24 Majority of the subjects with HRPH in our
study had significant dyspnoea when compared with the
others, with 50% of them in NYHA 3 and 4 though this did no
attain statistical significance. This finding is not supported by
that of Petitpretz et al,16 whose patients were in NYHA 1 and 2,
and younger. Again the privilege of early presentation and
diagnosis, aided with the benefit of cardiac catheterization
used by them, could have accounted for their results.
No association was seen between duration of highly active
anti-retroviral therapy (HAART) and HRPH. The effect of
HAART on presentation of HRPH is controversial, with some
reports suggesting that it modifies presentation, while others
differ.19 Some studies have reported that anti-retroviral ther-
apy (ART) can induce endothelial dysfunction in in-vitro
studies, and in animal models, resulting in increased
endothelin-1 production and endothelial proliferation and
thus potentially contributing to or exacerbating underlying
HRPH.25e27 The consensus being that for subjects who are not
already diagnosed with it, early commencement could
Table 5 e Correlation of mPASP with selected echocardiography parameters.
2DEcho/Doppler
parameter
Study population Mean Pearson correlation Correlation value p-value
EA ratio 200 1.44 0.066 Positive 0.07
EF 200 84.90 0.284 Negative <0.01
FS 200 35.00 0.208 Negative <0.01
DCT 200 192.34 0.128 Negative 0.09
IVSD 200 14.63 0.099 Positive 0.17
IVSS 200 12.08 0.004 Positive 0.96
IVRT 200 111.86 0.077 Positive 0.29
LVIDD 200 14.58 0.126 Positive 0.08
LVPWS 200 13.75 0.088 Negative 0.23
Correlation is significant at the 0.01 level (2-tailed).
FS: Fractional shortening, EF: Ejection fraction,DCT: Deceleration time, IVSD: Interventricular septum in diastole, IVSS: Interventricular septum
in systole, IVRT: Isovolumic relaxation time, IVSS: Intra-ventricular septum thickness in systole, LVIDD: Left ventricular internal diameter in
diastole, LVPWS: Left ventricular posterior wall thickness in systole.
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develops, HAART has no effect in its progression.
This study was stimulated by the cursory observation in
our practice that managing heart failure in HIV-infected
patients was more difficult, especially in those with evi-
dence of pulmonary hypertension. The findings have lent
credence to this assumption, as it was noticed that therewas a
negative correlation between pulmonary hypertension
(assessed by mean pulmonary arterial systolic pressure) and
such indices of left ventricular function as ejection fraction
and fractional shortening, as well as deceleration time, an
index of diastolic dysfunction. This is similar to the result of
Acikel et al28 who looked at the effect of pulmonary hyper-
tension on left ventricular diastolic dysfunction in chronic
obstructive disease. They found that deceleration time was
prolonged in subjects with pulmonary hypertension com-
pared to other patients, a finding that was replicated in ours
with a tendency to prolonged isovolumic relaxation time
(IVRT), and shortened deceleration time. The difference didFig. 1 e Scatter diagram correlating mean pulmonary
arterial systolic pressure with ejection fraction. EF: Ejection
fraction (%), mPASP: Mean arterial systolic pressure mm
(mmHg).not reach statistical significance. Among the subjects with
HRPH, 25% had evidence of LV systolic dysfunction, another
25% of diastolic dysfunction, while 12.5% had pericardial
effusion. This is a further confirmation of the deleterious
effect of untreated pulmonary hypertension on cardiac func-
tion, re-echoed among HIV-infected patients in a facility at
Washington DC, where diastolic dysfunction tended to be
more common in patients with pulmonary hypertension (60%
versus 36%), though the difference did not reach statistical
significance.156. Conclusion
This study has shown that HIV infection negatively affects
cardiac function and that coexisting pulmonary hyper-
tension independently contributes to both systolic and
diastolic dysfunction in the patients. The symptoms and
signs of both cardiac dysfunction and pulmonary hyper-
tension are subtle and similar to those of more common
ailments such as tuberculosis, other chest infections, and
anemia in HIV-infected patients. It is therefore imperative
that those who care for these patients should have a high
index of suspicion, so as to make early diagnosis, and
ensure appropriate and timely interventions. One way of
realising this is to encourage early cardiac assessment and
use of echocardiography in screening these patients whose
number is beginning to rise owing to the enhanced survival
attributable to HAART.Conflicts of interest
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